Loatro Eye Drop contains Atropine 0.01% w/v, a parasympatholytic agent used primarily for diagnostic and therapeutic purposes in ophthalmology. Atropine acts by competitively inhibiting muscarinic receptors in the eye, leading to pupil dilation (mydriasis) and paralysis of the ciliary muscle (cycloplegia). This facilitates comprehensive examination of the retina and other internal ocular structures while also providing relief from ciliary spasm associated with inflammatory conditions. Loatro Eye Drop is indicated for use in conditions such as uveitis, iritis, and amblyopia management, as well as for cycloplegic refraction in pediatric patients. The low concentration of 0.01% minimizes systemic absorption and reduces the risk of adverse effects, making it suitable for sensitive populations. Administration involves instillation of one or two drops into the affected eye(s) as directed by a healthcare professional, typically prior to ophthalmic examination or as part of a treatment regimen. Patients should be advised to avoid exposure to bright light due to increased photosensitivity and to refrain from activities requiring clear vision until the effects subside. Contraindications include hypersensitivity to atropine or related compounds, narrow-angle glaucoma, and certain cardiac conditions. Use with caution in children and elderly patients.